Which Country Is Fabrazyme (Agalsidase Beta) Cheapest In? — 2026 Guide

Why does the price differ so much between countries?

Fabrazyme (agalsidase beta) is a lyophilised 5 mg or 35 mg vial reconstituted and given by hospital or home-nursing intravenous infusion every two weeks, for life, to patients with Fabry disease — a rare X-linked lysosomal storage disorder. Because there is no cure and no dosing endpoint, a patient started on Fabrazyme in their twenties may remain on it for six decades, which makes the annuitised cost of manufacturing, cold-chain logistics and orphan-drug development recovery very different from a short-course oncology infusion. In Türkiye, the Ministry of Health anchors the reference price to the lowest ex-factory price found in a designated basket of EU member states, then converts it using the "pharmaceutical euro" (Dönemsel Avro Değeri) — fixed at 65% of the previous year's average Central Bank euro rate rather than the live spot rate. That mechanism, published via the TİTCK price list and gazetted in the Resmî Gazete, is the main reason Turkish list prices for orphan biologics sit structurally below free-pricing markets.

Competition for Fabrazyme is genuinely market-specific rather than uniform. Agalsidase alfa (Replagal) is authorised and marketed as a second enzyme replacement therapy for Fabry disease across the European Union and several other jurisdictions, giving payers there a comparator product to negotiate against. In the United States, Replagal has never been approved by the FDA, so Fabrazyme has historically faced no direct enzyme-replacement competitor domestically — a structural difference in market competition, not evidence of unfair pricing in either direction. Fabrazyme's own history includes well-documented manufacturing shortages between 2009 and 2012 that led to rationed dosing in several countries, a supply episode that shaped how regulators and clinicians since have thought about single-source orphan biologics.

Germany evaluates Fabrazyme's benefit under its AMNOG framework, where a manufacturer sets a free price for the first six months of a new indication before a negotiated price applies, backdated to month seven. The United Kingdom's NICE ordinarily applies a cost-per-QALY threshold that was raised from the long-standing £20,000–£30,000 band to £25,000–£35,000, announced 1 December 2025 and effective from April 2026 (see NICE) — but for a disease as rare as Fabry, NICE instead typically routes evaluation through its separate Highly Specialised Technologies (HST) programme, which applies a distinct, more permissive cost-effectiveness framework recognising that ultra-rare conditions cannot generate the same evidence base as common cancers.

The United States has no equivalent government reference mechanism for a lifelong orphan biologic like Fabrazyme: pricing is largely free at launch and negotiated privately between the manufacturer, payers and specialty pharmacy benefit managers. Most patients never encounter a list price directly because Fabrazyme is dispensed through hospital or specialty infusion pharmacies under insurance or national-health-system funding, with substantial confidential rebates at the payer level. For the underlying mechanics of why Türkiye's published prices sit where they do, see our explainer on why medicines cost less in Türkiye.

How is the price set in each country?

The table below compares pricing systems, not prices. Each country publishes — or does not publish — its own official list, and that published list is the only figure worth relying on. Follow the link in the last column and read the current entry yourself.

How can I obtain a medicine legally from a lower-price market?

There is a lawful route in most countries, and it starts in the same place everywhere: a valid prescription in your own name, issued by the physician treating you. What differs is the import permit. The procedures below are stated only where they could be verified at the national authority.

United Arab Emirates. MOHAP operates a permit to import medicines for personal use through its Electronic Drug Establishment service. The permit is free and is issued within 3 working days. You log in with a MOHAP account or UAE Pass.

Saudi Arabia. Applications run through the SFDA Controlled Drugs System at cds.sfda.gov.sa, under a guideline published on 14 August 2025. Read the current SFDA regulations page before you travel — the requirements are revised periodically.

Qatar. For non-controlled medicines there is no pre-approval: you may carry up to a 60-day supply through the Green Channel, in the original packaging, with a copy of the prescription and a signed, stamped letter from your doctor. For controlled medicines you need advance approval and must use the Red Channel; supporting documents must be no older than 6 months and in Arabic or English.

Kuwait and Azerbaijan. Confirm the current procedure directly with the national authority before shipping or travelling — Kuwait Ministry of Health and Azerbaijan Tariff Council. We do not publish a step list for these two countries because the procedure could not be verified at source.

1. United Arab Emirates — obtain a prescription in the applicant's own name, issued within the last 3 months.
2. Obtain a medical report from the treating facility, authenticated by the health authority and issued within the last year.
3. Prepare an Emirates ID or passport copy for the applicant.
4. Log in to the MOHAP service with a MOHAP account or UAE Pass and submit the personal-import application.
5. Keep the quantity within the limit: no more than a 1-month supply for controlled medicines, and no more than a 3-month supply for non-controlled medicines.
6. Wait for the decision — the service is free and normally issued within 3 working days.
7. Contact MOHAP on 800 111 11 or at import.export@mohap.gov.ae if the application stalls.

What is named patient supply?

Named patient supply is the international concept behind almost every lawful cross-border medicine route. The clearest codified example is the United Kingdom's MHRA Guidance Note 14, built on Regulation 167 of the Human Medicines Regulations 2012.

Four conditions define it: the order must be unsolicited; the product must be specified by the prescriber; the prescriber must be directly responsible for the patient; and there must be a genuine special clinical need that no authorised product meets.

The honesty point matters here: the European Court has held that "financial considerations cannot, in themselves" establish a special clinical need. A lower price in another country is not, by itself, a lawful basis for a named-patient import. The lawful bases are clinical.

Is the Fabrazyme I'm being offered genuine?

No falsified batches of Fabrazyme have been recorded in WHO's alert series to date. That is a genuinely reassuring fact about this specific product's track record, but it is not a reason to relax verification: Fabrazyme is a lifelong, single-source biologic dispensed almost exclusively through hospital and home-infusion pharmacies, and any offer of it outside that channel — particularly across borders — should be treated with the same scrutiny you would apply to any high-value cold-chain biologic.

Because Fabry disease is rare and Fabrazyme has a documented history of supply shortages, patients and caregivers sometimes feel pressure to source doses through informal channels when local stock runs low. That pressure is exactly the scenario counterfeiters exploit in other therapeutic areas, so a genuine local shortage is a reason to contact Sanofi Genzyme or your treating centre directly, not to accept an unverified vial from an unfamiliar supplier.

• Scan the carton's GS1 DataMatrix and confirm it decodes to AI 01 (GTIN), AI 21 (serial number), AI 17 (expiry) and AI 10 (batch) — a code that will not scan, or scans to the wrong product, is a hard stop.
• If the vial is sourced in Türkiye, check that its karekod is notified to the national İlaç Takip Sistemi (İTS) track-and-trace system at its.saglik.gov.tr before it leaves the pharmacy.
• Ask for a continuous 2–8°C temperature log covering the actual shipment you are receiving, not a generic cold-chain certificate — Fabrazyme must never be frozen or shaken.
• Confirm reconstitution takes place only in a licensed hospital or home-infusion pharmacy immediately before administration, never pre-mixed and shipped.
• No falsified batches of Fabrazyme have been logged in WHO's alert series to date; cross-check any concern against our WHO falsified medicine alerts tracker rather than assuming the absence of a listing means informal sourcing is safe.
• Be suspicious of any supplier offering Fabrazyme without a hospital or specialist-clinic prescription — legitimate supply for a lifelong orphan therapy never bypasses the treating centre.
• Review the full verification workflow in our guide to checking that a medicine is genuine.

Frequently asked questions

Sources

• Resmî Gazete — Beşeri Tıbbi Ürünlerin Fiyatlandırılmasına Dair Karar No. 11031 — retrieved: 2026-07-28
• TİTCK — published medicine price list — retrieved: 2026-07-28
• MOHAP (UAE) — import medicine for personal use — retrieved: 2026-07-28
• SFDA (Saudi Arabia) — regulations — retrieved: 2026-07-28
• SFDA Controlled Drugs System — retrieved: 2026-07-28
• Qatar MOPH — drug prices — retrieved: 2026-07-28
• Kuwait Ministry of Health — retrieved: 2026-07-28
• Azerbaijan Tariff Council (Tarif Şurası) — retrieved: 2026-07-28
• NICE (United Kingdom) — retrieved: 2026-07-28
• G-BA (Germany) — AMNOG benefit assessment — retrieved: 2026-07-28
• RAND — International prescription drug price comparisons (published 1 Feb 2024) — retrieved: 2026-07-28
• Frontiers in Pharmacology — European hospital price transparency study (9 Mar 2026) — retrieved: 2026-07-28
• MHRA Guidance Note 14 — supply of unlicensed medicinal products — retrieved: 2026-07-28

Country availability pages for this medicine

Related pages

Enzyme replacement therapies

Related high-cost medicines